Vincristine Teva 1 mg/1 ml 1ml

Vincristine Teva 1 mg/1 ml 1ml

$10.00

Vincristine 1 mg/1 ml is used to treat various types of cancer. It is a cancer chemotherapy drug that is usually used with other chemotherapy drugs to slow or stop cancer cell growth.

Availability: 1 in stock SKU: 2404 Category: Tags: , , , , , , , ,
  • Description
  • Additional information
  • Doses and Uses
  • Shipping & Payment
  • Reviews (0)

Description

Buy online Vincristine Sulfate 1 mg/ml solution for injection.
Each 1 ml contains 1.0 mg of vincristine sulfate.
Excipient with known effect: benzyl alcohol (9 mg per ml).

Vincristine is used to treat various types of cancer. It is a cancer chemotherapy drug that is usually used with other chemotherapy drugs to slow or stop cancer cell growth.

INDICATIONS
Vincristine sulfate injection (vincristine sulfate) is indicated in acute leukemia.
Vincristine sulfate injection (vincristine sulfate) has also been shown to be useful in combination with other oncolytic agents in Hodgkin’s disease, non-Hodgkin’s malignant lymphomas (lymphocytic, mixed cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor.

Vincristine sulfate is used either alone or in conjunction with other oncolytic drugs for the treatment of:

  • Leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic myelogenous leukaemia;
  • Malignant lymphomas, including Hodgkin’s disease and non-Hodgkin’s lymphomas;
  • Multiple myeloma;
  • Solid tumours, including breast carcinoma, small cell bronchogenic carcinoma, head and neck carcinoma and soft tissue sarcomas;
  • Paediatric solid tumours, including Ewing’s sarcoma, embryonal rhabdomyosarcoma, neuroblastoma, Wilms’ tumour, retinoblastoma and medulloblastoma;
  • Idiopathic thrombocytopenic purpura. Patients with true ITP refractory to splenectomy and short-term treatment with adrenocortical steroids may respond to Vincristine but the medicinal product is not recommended as primary treatment of this disorder. Recommended weekly doses of Vincristine given for 3 to 4 weeks have produced permanent remissions in some patients. If patients fail to respond after 3 to 6 doses, it is unlikely that there will be any beneficial results with additional doses.

CONTRAINDICATIONS
Intrathecal administration of Vincristine sulfate is usually fatal.

Hypersensitivity to Vincristine sulfate or to any of the excipients.

Patients with the demyelinating form of Charcot-Marie-Tooth syndrome should not be given Vincristine.

As Vincristine Sulfate solution for injection contains benzyl alcohol it must not be given to premature babies or neonates.

PRECAUTIONS

  • Before using vincristine, tell your doctor or pharmacist if you are allergic to it or to vincristine liposomal; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details;
  • Before using this medication, tell your doctor or pharmacist your medical history, especially of: nerve/muscle problems (such as numbness/tingling/pain due to neuropathy, demyelinating conditions including Charcot-Marie-Tooth syndrome), liver disease, radiation treatment to the liver, decreased bone marrow function, blood disorders, current infection;
  • This medication can make you more likely to get infections or may worsen any current infections. Therefore, wash your hands well to prevent the spread of infection. Avoid contact with people who have infections that may spread to others (such as chickenpox, measles, flu). Consult your doctor if you have been exposed to an infection or for more details;
  • Do not have immunizations/vaccinations without the consent of your doctor. Avoid contact with people who have recently received live vaccines (such as flu vaccine inhaled through the nose);
  • To lower the chance of getting cut, bruised, or injured, use caution with sharp objects like razors and nail cutters, and avoid activities such as contact sports;
  • This drug may make you dizzy or tired or cause numbness in your hands/feet. Alcohol or marijuana can make you more dizzy or tired. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana;
  • Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products);
  • Children may be more sensitive to the effects of this drug, especially slowed movement of the gut that may cause vomiting and constipation;
  • Elderly patients who also take drugs that may cause difficult urination as a side effect may be more sensitive to the effects of this drug on the kidneys (urinary retention). Consult your doctor for more details. See also Drug Interactions;
  • This medication may reduce fertility in men and women. Consult your doctor for more details;
  • This medication is not recommended for use during pregnancy. It may harm an unborn baby. Discuss the use of reliable forms of birth control (such as condoms, birth control pills) with your doctor;
  • It is not known whether this drug passes into breast milk. Because of the possible risk to the infant, breast-feeding while using this drug is not recommended. Consult your doctor before breast-feeding.

INTERACTION

  • Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor’s approval;
  • Some products that may interact with this drug include: digoxin, phenytoin, drugs that may cause nerve damage to the ear (e.g., chemotherapy drugs that contain platinum), drugs that may cause difficult urination (e.g., belladonna alkaloids, anticholinergic drugs such as atropine, antispasmodics such as dicyclomine, drugs to treat an overactive bladder such as oxybutynin);
  • Other medications can affect the removal of vincristine from your body, which may affect how vincristine works. Examples include azole antifungals (such as itraconazole), macrolide antibiotics (such as erythromycin), rifamycins (such as rifabutin), St. John’s wort, drugs used to treat seizures (such as carbamazepine), among others.

SIDE EFFECTS
Side effects following the use of Vincristine are dose related. In children under 13 years of age, death has occurred following doses of Vincristine that were 10 times those recommended for therapy. Severe symptoms may occur in this patient group following dosages of 3 to 4 mg/m2. Adults can be expected to experience severe symptoms after single doses of 3 mg/m2 or more. Therefore, following administration of doses higher than those recommended patients can be expected to experience side-effects in an exaggerated fashion.
Nausea, vomiting, weight loss, diarrhea, mouth sores, dizziness, or headache may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

This medication can also cause constipation, which in some cases may become serious. Consult your doctor or pharmacist about how you can prevent constipation (such as eating a diet high in fiber, drinking plenty of water). Ask about regularly using a stool softener such as docusate, avoiding bulk-forming laxatives, and choosing a stimulant laxative. Tell your doctor or pharmacist promptly if you develop constipation, stomach/abdominal pain, or bloating.

Temporary hair loss may occur. Normal hair growth should return after treatment has ended.

People using this medication may have serious side effects. However, your doctor has prescribed this drug because he or she has judged that the benefit to you is greater than the risk ofside effects. Careful monitoring by your doctor may decrease your risk.

This medication may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. Tell your doctor right away if you have any signs of infection (such as fever, chills, persistent sore throat, cough).

This medication commonly affects the nerves and muscles in your body. Most of these side effects go away after this medication is stopped, however some effects may persist for a long time. Tell your doctor right away if you have any of the following: painful/difficult urination, decreased urination, pain (including in the joints, back, muscles), numbness/tingling/burning/pain of the feet/hands, weakness, difficulty walking, loss of coordination/balance, inability to move your muscles (including the muscles of your face and other parts of your body), drooping eyelids, hoarseness, trouble speaking.

Tell your doctor right away if you have any serious side effects, including: vision/hearing changes, mental/mood changes (such as depression, hallucinations, confusion), easy bleeding/bruising, severe tiredness.

Get medical help right away if you have any very serious side effects, including: seizures, chest/jaw/left arm pain, signs of liver problems (such as dark urine, persistent nausea, vomiting, stomach/abdominal pain, yellowing eyes/skin).

Trouble breathing may rarely occur with Vincristine treatment, especially when it is given with another chemotherapy drug, mitomycin-C. Patients with lung problems may be more sensitive to this side effect. Long-term treatment of this side effect may be required if it worsens. This effect may occur within minutes to several hours after Vincristine is given and up to 2 weeks after the dose of mitomycin-C. Get medical help right away if you have shortness of breath or coughing. If you have this reaction, you should not receive Vincristine again.

A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any of the following symptoms of a serious allergic reaction: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

REALESE FORM
Solution for injection.
A sterile, colourless solution.

STORAGE
Store Vincristine in a refrigerator (2°C – 8 °C). Keep the vial in the outer carton, in order to protect from light.

Additional information

Weight 150 g
Forms of release

Solutions for injections

Volume / Weight

1 ml

Packing

Vial

Manufacturer

Pharmachemie

Country/Region of Manufacture

Netherlands

Expiration date

04.2020

This preparation is for intravenous use only.

Neurotoxicity appears to be dose related. Extreme care must be used in calculating and administering the dose of Vincristine Sulfate Injection, USP (vincristine sulfate) since overdosage may have a very serious or fatal outcome.

Special Dispensing Information: WHEN DISPENSING VINCRISTINE SULFATE INJECTION (vincristine sulfate) , USP IN OTHER THAN THE ORIGINAL CONTAINER, IT IS IMPERATIVE THAT IT BE PACKAGED IN THE PROVIDED OVERWRAP WHICH BEARS THE FOLLOWING STATEMENT: “DO NOT REMOVE COVERING UNTIL MOMENT OF INJECTION. FATAL IF GIVEN INTRATHECALLY. FOR INTRAVENOUS USE ONLY” (see WARNINGS). A syringe containing a specific dose must be labeled, using the auxiliary sticker provided, to state: “FATAL IF GIVEN INTRATHECALLY. FOR INTRAVENOUS USE ONLY.”

The concentration of Vincristine Sulfate Injection, USP (vincristine sulfate) is 1 mg/mL. Do not add extra fluid to the vial prior to removal of the dose. Withdraw the solution of Vincristine Sulfate Injection, USP (vincristine sulfate) into an accurate dry syringe, measuring the dose carefully. Do not add extra fluid to the vial in an attempt to empty it completely.

Caution: It is extremely important that the intravenous needle or catheter be properly positioned before any vincristine is injected. Leakage into surrounding tissue during intravenous administration of Vincristine Sulfate Injection, USP (vincristine sulfate) may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage will help disperse the drug and may minimize discomfort and the possibility of cellulitis.

Vincristine Sulfate Injection, USP (vincristine sulfate) must be administered via an intact, free-flowing intravenous needle or catheter. Care should be taken that there is no leakage or swelling occurring during administration (see BOXED WARNINGS).

The solution may be injected either directly into a vein or into the tubing of a running intravenous infusion (see Drug Interactions below). Injection of Vincristine Sulfate Injection, USP (vincristine sulfate) should be accomplished within 1 minute.

The drug is administered intravenously at weekly intervals.

The usual dose of Vincristine Sulfate Injection, USP (vincristine sulfate) for pediatric patients is 1.5-2 mg/m². For pediatric patients weighing 10 kg or less, the starting dose should be 0.05 mg/kg, administered once a week. The usual dose of Vincristine Sulfate Injection, USP for adults is 1.4 mg/m². A 50% reduction in the dose of Vincristine Sulfate Injection, USP (vincristine sulfate) is recommended for patients having a direct serum bilirubin value above 3 mg/100 mL.

Vincristine Sulfate Injection, USP (vincristine sulfate) should not be given to patients while they are receiving radiation therapy through ports that include the liver. When Vincristine Sulfate Injection (vincristine sulfate) , USP is used in combination with L-asparaginase, Vincristine Sulfate Injection, USP (vincristine sulfate) should be given 12 to 24 hours before administration of the enzyme in order to minimize toxicity; administering L-asparaginase before Vincristine Sulfate Injection, USP (vincristine sulfate) may reduce hepatic clearance of Vincristine.

STANDART SHIPPING WORLDWIDE
WEIGHT (kg) COST ($US) ESTIMATED

DELIVERY TIME

TRACKING
0 - 0.199 6.50 15 - 21 working days Available
0.200 - 0.250 8.00 15 - 21 working days Available
0.251 - 0.500 14.00 15 - 21 working days Available
0.501 - 1.000 20.00 15 - 21 working days Available
1.000 - 2.000 25.00 15 - 21 working days Available

PAYMENT

  • We accept Visa, MasterCard via AdvCash & Payeer (there are problems with the possibility).
  • We accept SEPA, BACS.
  • We accept RIA.
  • We accept Cryptocurrency.
  • PayPal.

Depending on the method of payment, additional Fees / VAT are charged.

And also there is a system of bonuses that you can spend on your next purchases.

Reviews

There are no reviews yet.


Only logged in customers who have purchased this product may leave a review.

You've just added this product to the cart: